Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Vanillyl butyl ether carries a story spanning decades, rooted in the traditions of organic chemistry laboratories from the early 1900s. Scientists once wrestled with extracting vanillin from vanilla beans and finding ways to unlock new applications. By coupling vanillin with butyl groups, they paved the way for novel uses and improved molecular stability. Through the mid-20th century, pharmaceutical and cosmetic industries leaned into such derivatives, hoping to develop agents offering more than just flavor. Over time, more regulatory bodies established safety standards, making sure that each produced batch fit the rising demands of medical applications. My reading into pharma innovation archives consistently points to an evolution marked by meticulous research, informed curiosity, and careful regulation.
Vanillyl butyl ether stands out for its gentle warming sensation when absorbed by skin. In the pharmaceutical world, it gets formulated for topical treatments designed to soothe or deliver active drugs effectively. The ether's mild sensory profile makes it popular in skin creams that aim to avoid harsh irritation, commonly favored by product developers who want a reliable warming agent. Pharmaceutical-grade vanillyl butyl ether, labeled under BP, EP, or USP standards, undergoes strict quality checks so it matches the purity and performance expectations set by industry and regulators.
This compound offers a clear, almost colorless oil at room temperature and boasts a faint, sweet scent reminiscent of vanilla. Its molecular structure assists penetration through skin layers while guarding against unwanted volatility. With a melting point well below freezing and high solubility in oils and alcohols, it mixes smoothly into topical formulations or liquid pharmaceuticals. The distinct chemical resilience of the benzene ring and ether linkage helps it persist under various storage and application environments, something formulators appreciate when seeking long-term shelf stability.
Pharma-grade vanillyl butyl ether meets specifications for purity, trace contaminant thresholds, and identification tests aligned with BP, EP, and USP monographs. For ease in manufacturing and end-use, labels must reflect content of active ether, lot number, and possible residual solvents. Documentation on analytical methods, such as HPLC chromatograms and IR spectra, accompanies every shipment. The product’s certificate of analysis stands as proof for compliance and expected biological performance, a practice directly supporting both quality assurance and regulatory traceability from production plant to patient.
Large producers rely on a condensation process combining vanillin with n-butyl bromide, facilitated by either base or acid catalysis, depending on the target throughput and solvent considerations. This reaction, rooted in etherification chemistry, helps yield high-purity vanillyl butyl ether when performed under strict anhydrous conditions. Every batch can require column purification and repeated testing for byproducts like unreacted vanillin or excess butyl halide. For smaller laboratories, bench-scale synthesis replicates these steps on a tighter control frame, allowing rapid optimization as pharmaceutical demands shift.
Reaction chemists approach vanillyl butyl ether’s modification from the perspective of enhancing its skin absorption or longevity. The phenolic structure lends itself to further substitution, and many derivative esters or amides see development for specialty medical applications. Hydrogenation can tune the scent or improve the stability for storage under harsh conditions. I’ve read about attempts to conjugate it with peptides, bridging gaps between cosmetic and therapeutic uses. Observing new patents, it’s clear the chemistry remains a playground for innovation, particularly where increased efficacy and reduced sensitivity matter.
Across catalogs and regulatory documents, this molecule appears as VBE, butyl vanillate, or 4-hydroxy-3-methoxybenzyl butyl ether. Some cosmetic brands list it as Senshot or Hotact VBE, highlighting the warming effect in ingredient lists. On pharmaceutical packaging, expect its monograph name, matched to the applicable BP, EP, or USP standard, with alternate names only as cross-references for pharmacists checking authorized substitutions.
Strict guidelines oversee the use of vanillyl butyl ether in health products. Manufacturing workplaces institute localized ventilation and closed systems for handling concentrated raw material. Labels detail exposure hazards, including possible mild skin or eye irritation at high concentration. GHS-compliant documents lay out emergency protocols, and most guidelines recommend nitrile gloves and eye protection. Any deviation during the batch synthesis triggers quality checks and potentially full investigation to protect workers and end-users. For warehouse storage, fire safety and chemical compatibility lists are reviewed regularly, since ether bonds carry fire risk with careless handling.
You find vanillyl butyl ether at work in topical rubefacients that relieve minor muscle and joint discomfort. It serves as a mild counterirritant: warming the skin gently and delivering relief where stronger agents might cause burning or redness. Beyond the pharmacy, its warming action brings value to foot creams, sports balms, and selective personal care products. In Japan and South Korea, beauty products feature this compound for its gentle sensation, adding a perceived boost to circulation and comfort. Some clinical studies explore whether the compound’s warming helps drive actives deeper into skin, providing a kind of booster seat for modern transdermal therapies.
Development teams track trends in consumer sensitivity and demand for cleaner ingredient profiles. R&D labs experiment with new formulations improving compatibility of vanillyl butyl ether alongside actives such as NSAIDs, lidocaine, or plant extracts. Other researchers pursue synergistic effects, blending it with capsaicin or menthol to create tailored warming-cooling sensations. Recent journal articles report efforts to microencapsulate the ether, controlling its release profile and improving its shelf-life. Clinical researchers keep an eye out for rare but notable cases of allergic response, documenting these in safety reviews. All this signals a field alive with experimentation, guided by both tradition and new consumer expectations.
Toxicologists ran acute and chronic exposure studies in rodents, showing low systemic toxicity at levels far above therapeutic use. Irritation testing, both in vitro and on volunteers, found only mild irritation above five percent concentration in finished product. Regulatory agencies set exposure limits and warn against direct eye contact, but no mutagenic or carcinogenic effects surfaced in standard testing. The skin’s barriers do a good job stopping significant absorption, so systemic effects stay rare outside experimental dosing. Recent safety reviews flagged rare allergic reactions, mainly in people already sensitized to vanillin derivatives, steering dermatologists towards caution when recommending new products.
New manufacturing technologies promise greener, lower-waste production routes, cutting down on petrochemical starting materials and solvents. More formulators seek to blend the warming action of vanillyl butyl ether with next-generation delivery systems, including nanoparticles and multilayer films. With the global shift toward more transparent ingredient labeling and sustainability, every actor in the supply chain faces a call to document environmental impacts and social responsibility. Researchers keep looking for novel analogues offering increased potency with even milder sensory impact, hoping to expand the use of vanillyl butyl ether beyond pain relief into wellness, skincare, and perhaps even advanced medication delivery. As the ingredient’s track record grows, clinicians and developers alike debate the balance between sensory benefit and risk management, a tension certain to spark more innovation and scrutiny as new applications emerge.
Vanillyl Butyl Ether sounds like one of those substances that belong in a high school science class, but dig into the details and you’ll spot its name printed on pharmaceutical ingredient lists. This compound can seem mysterious for folks outside the lab, though it quietly plays a noticeable role in both medicine and personal care circles.
Imagine applying a cream or ointment and feeling gentle warmth on your skin. That comfort doesn’t just appear by magic or a trick of the imagination. Vanillyl Butyl Ether creates that sensation, and it does so in a way that’s less harsh than using traditional warming ingredients like capsaicin. There’s no tingling burn that sends you running for soap and water—just a mild, comforting heat. This makes topical creams for sore muscles or certain medicated patches more pleasant and less likely to cause irritation.
Athletes and anyone managing aches or tightness rely on topical pain relief products. Old-school heat rubs sometimes sting or burn or even cause rashes. Pharmaceutical companies caught onto the milder heating profile of Vanillyl Butyl Ether and started adding it to their muscle rubs and patches. It doesn’t just mask pain; the warmth helps encourage blood flow, which supports the body’s own repair process. Less discomfort means more people keep moving and stay active, and that’s a real benefit as populations age.
Some skin care products aim to be more than just functional. Lip plumpers, slimming creams, and scalp treatments line up on shelves, promising a sensory experience as much as a physical result. That gentle heating effect leaves users with a sense of activity and freshness. Unlike harsher chemicals, this compound rarely causes redness or unexpected side effects. Those developing new products notice that customers want experience, not just effectiveness, which drives interest in gentler warming ingredients.
Vanillyl Butyl Ether marked as BP, EP, or USP Pharma Grade signals something important: manufacturers follow internationally recognized standards. Nobody wants contamination in pain relief gels or cosmetics. Consistency matters for patient and consumer safety, and rigorous quality controls go a step further—ensuring every tube or bottle delivers predictable results. Regulations in North America, Europe, India, and beyond require ingredient transparency, especially as public knowledge about cosmetic and pharma safety grows year after year.
The days of adding new ingredients without much testing are over. Consumers expect more information on what they put on their bodies. Research about Vanillyl Butyl Ether has expanded, giving a clearer view of effective ranges and how it interacts with skin. More small startups and big brands alike are running their own trials, listening to feedback, and looking for ways to improve long-term comfort. As the pharmaceutical and beauty industries keep evolving, ingredients with a good safety record and strong regulatory backing tend to gain ground. That way, both health professionals and consumers get the benefit of comfort—and hopefully, a little more peace of mind.
Vanillyl Butyl Ether, often known in pharmaceutical circles for its warming effect, plays a unique role in topical formulations and sensory products. Meeting pharmaceutical grade means satisfying strict standards—BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) share common ground on many of these demands. The basics are straightforward: heavy focus on chemical purity, no unwanted additives, and predictable performance every time.
Each pharmacopeia presses hard on purity. This isn’t just about looking good on paper—impurities, even at trace levels, can cause reactions or skew research. In the BP, Vanillyl Butyl Ether must usually hit a chemical purity above 98%. The EP and USP echo this bar, with a heavy hand on consistent assay values and defined allowable impurities. Any sign of heavy metals, residual solvents, or related substances needs tight control and clear documentation.
From a scientific perspective, this focus on narrow specifications keeps professionals confident in their ingredients. When I worked alongside formulating pharmacists, I saw how even a tiny deviation raised red flags and delayed product launches. Regulators expect every batch to show the same chromatographic profile — year after year, batch after batch.
Beyond raw purity, standards include physical descriptions: colorless to pale yellow liquid, barely any odor, and measured refractive index and specific gravity. Each of these qualities signals consistency to both manufacturers and auditors. Even water content can’t be shrugged off, as too much moisture hints at mishandling or future instability.
Many compendia set strict limits here, almost always below 0.5% for water. Experience in quality testing teaches patience—moisture shifts fast with careless storage and can flip a certificate of analysis from compliant to rejected overnight.
Impurities present one of the trickiest hurdles. Heavy metals such as lead, cadmium, and mercury undergo testing at parts-per-million or billion levels. Solvents left from synthesis—think methanol or toluene—must fall far below established safety limits. For the pharma grades, the allowable solvent residue drops to almost negligible: usually under 0.5% for common classes, with special attention for any solvents flagged as toxic.
In real-world production, these tests demand not only skill but strong relationships with reliable suppliers. Once, a batch from a new vendor failed on arsenic—despite having “pharma grade” on the label. That episode taught me to trust certificates from respected labs rather than marketing claims.
BP, EP, and USP expect absence of bacterial contamination and low total microbial counts. This requirement protects those using finished products—nobody wants an infection risk from a topical cream. It also impacts shelf life, as microbial growth spells faster breakdown and recalls.
Careful handling and closed systems keep numbers low. Especially in injectable-grade substances, skipping a quality step just to save money leads to consequences nobody wants on their conscience.
Insisting on pharma grade stretches beyond regulatory compliance. These standards protect patients, build trust between brands and users, and ease approval of new medicines. Staying up to date with changing pharmacopeial requirements, testing every lot, and working with transparent suppliers keeps everyone safer and products more effective.
Vanillyl Butyl Ether pops up in more products than most folks realize. It serves as a warming agent, offering a mild, pleasant heat sensation in both topical pharmaceuticals and personal care items. The United States Pharmacopeia (USP), the British Pharmacopoeia (BP), and the European Pharmacopoeia (EP) all set out tight standards for purity and safety. Pharmaceutical-grade versions of Vanillyl Butyl Ether must meet tough checks. In cosmetics and pharma, especially ones that come into direct contact with skin, meeting these checks matters for trust and safety.
Plenty of research has gone into the safety profile of Vanillyl Butyl Ether. Studies carried out under controlled settings show that it rarely triggers skin irritation or allergic reactions at typical concentrations. You’ll find it in creams to manage joint or muscle pain and as a warming additive in lip plumpers and lotions. Regulatory bodies, including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), evaluate such compounds regularly for both irritation and potential toxicity. Neither group has flagged Vanillyl Butyl Ether as a high-risk ingredient at these pharma-grade levels.
What trumps everything in health care or cosmetics: transparency. Manufacturers publish safety data and test results, and both patients and end-users have better options as a result. Those with ultra-sensitive skin or known allergies always have to check labels and look for alternatives if they notice any discomfort or redness, as personal biology can override even the best research. Reputable manufacturers batch-test their offerings and make these results available upon request. This level of transparency gives users a real sense of control and builds loyalty.
No ingredient lands in a cream or medicine without a paper trail. Every batch of pharmaceutical-grade Vanillyl Butyl Ether passes though audits set up by national health agencies, independent labs, and internal company checks. The BP, EP, and USP require identification of impurities, heavy metals, and microbes. Any shipment not matching those benchmarks gets rejected. In that sense, the risk bleeding through to patients or customers stays about as low as humanly possible.
Most safety scares in the pharmaceutical and cosmetic world come from corners where shortcuts sneak in. Think: suppliers skimping on tests or brands looking for quick releases. Working with trustworthy ingredients relies on steady, ongoing checks. Some companies in the industry run extra screens beyond statutory minimums. They see this as a way to guard their reputations, meet global regulatory demands, and earn customer trust for the long haul.
Continuous education plays a big part in keeping Vanillyl Butyl Ether use within safe margins. Health professionals, regulatory officers, and consumers benefit from regular access to updated studies and openly published adverse event reports. Using tools like QR codes on packaging, pharmacists and patients can pull up Certificates of Analysis and test results on the spot. This approach puts control into the hands of anyone interacting with the product.
Developing and enforcing strict sourcing policies, along with putting money into better analytical testing, keeps risk close to zero. When a manufacturer listens to feedback, posts frequent updates, and makes lab results easy to check, it gains an edge in a crowded market. Looking ahead, demand for both transparency and stricter quality marks will only rise. Regular conversations about real-world user experience sharpen those safety margins even more.
Every time I walk into a pharmaceutical facility or chat with chemists, I see how much thought working teams give to packaging raw materials—especially chemicals like Vanillyl Butyl Ether. This ingredient, prized for its warming sensation in topical pharma applications, rewards those who treat it with respect during storage and transit. Nobody cuts corners here, because the risk to product quality feels real, not theoretical.
Pharma-grade Vanillyl Butyl Ether usually comes in closed, high-density polyethylene (HDPE) drums or bottles. Glass containers sometimes make an appearance, mostly for smaller samples or lab-scale needs. The goal is always the same: keep out moisture, air, and UV light. Even before regulations come into play, anyone responsible for sourcing and storing active chemicals knows that leaky, poorly sealed barrels can mean contamination or loss of potency. I’ve seen far too many facilities deal with the nightmare of a shipment gone bad because someone chose the wrong lid or storage room.
Twenty-kilogram HDPE drums often get selected for moderate and large orders. Their advantage comes from toughness and a good seal. Small labs and specialty R&D groups turn to smaller bottles, sometimes with amber glass for extra light protection. Tamper-evident seals provide confidence for buyers. Security strips, serialized barcodes, and detailed batch labels back up pharma companies if anyone ever needs to trace an issue.
Vanillyl Butyl Ether typically lasts about two years when left unopened and kept away from heat, humidity, and direct sunlight. This two-year number gets thrown around a lot, and for good reason—it’s not just about what the chemical “should” last, but what actually gets observed after months or years in storage. I’ve watched stock managers scramble to rotate inventory after summer heat waves or during power outages, because real shelf life always depends on vigilance, not just paperwork.
Heat makes all the difference. You can write “cool, dry, and well-ventilated” on every storage room in the world, but if the air conditioning fails or the drums stand too close to hot machinery, you risk the ether degrading or even pressure building up inside the container. Left exposed to light, the product color may darken, raising doubts about purity and stability. Moisture, too, gets inside cheap or poorly sealed containers faster than you’d think, opening the door to hydrolysis and all manner of spoilage headaches.
After opening a drum, shelf life drops—sometimes to less than a year. I tell clients to use the chemical soon after breaking the original seal. Leftovers in smaller containers should get closed up tight, ideally under nitrogen or dry air, if there’s a chance they’ll sit around. Even then, don’t expect miracles. Every time you open a lid, contamination or oxidation can sneak in.
Choosing packaging without thinking about the actual shipping route, local climate, or warehouse setup runs up costs in the long run. I’ve walked through sites that repackage bulk drums into smaller sterilized bottles just to cope with humidity swings during monsoon season, or to cut down on theft and spillage during regional transport. That kind of adaptation doesn’t just check a compliance box—it often saves the batch project from loss or recall.
Modern supply chains push for traceability and accountability. Smart barcoding and real-time tracking help teams catch mistakes before they reach patients. At the end of the day, shelf life and integrity stem from choices around packaging, storage, and real-world vigilance. Relying on habits, not just regulations or supplier promises, keeps quality high and risk low.
Handling any pharmaceutical-grade compound brings a unique set of responsibilities. Vanillyl Butyl Ether has built a strong reputation for its warming sensation in topical and cosmetic applications. High purity matters, but so does the way the ingredient gets handled from the warehouse to the workbench.
Nobody relishes product loss due to sloppy storage. Vanillyl Butyl Ether has a low odor and clear appearance, which makes spills harder to notice. Having worked with similar raw materials, I’ve learned that a careless mistake can turn costly fast. Supporting proper storage not only preserves quality but also upholds safety, especially in a busy facility.
Temperature impacts Vanillyl Butyl Ether more than most assume. The compound stays stable around 25°C, so cool, controlled spaces keep it from degrading. Sunlight hastens breakdown, which risks inconsistent results when formulating or manufacturing. Store this ether in a dark, tightly sealed container to keep both light and air out of the equation. In the industry, amber glass or opaque HDPE containers often prove most reliable. Oxygen can trigger slow oxidation, so make sure the lid returns to the drum after every use.
I’ve faced the consequences of ignoring these basic rules. Once, a supplier sent a drum with an unsealed cap. The product showed unexpected discoloration within weeks, creating downtime and a raft of paperwork to explain the mistake. Pharmaceutical standards don’t leave wiggle room for such errors.
Pharma grade always means an extra layer of caution. Gloves and goggles matter during transfer, especially since the compound can be an irritant. Don’t underestimate how easily dust or tiny particles slip into open containers. I recommend setting up a clean, isolated area for weighing or transferring this chemical, away from other ingredients. Train every team member on what cross-contamination means for patient safety. Regular audits keep everyone honest and reinforce best practices.
Keeping ironclad batch records transforms quality control from a box-ticking exercise into real peace of mind. Date every transfer. Record temperatures and run regular checks on storage spots. Any time I've overlooked the logbook, confusion followed. Auditors look for this paper trail and it helps track down any issues if they arise. Digital systems add another layer of reliability, especially for tracing expiration or investigating complaints.
International standards—like those in the USP, EP, and BP monographs—make no exceptions for improper handling. Many pharma plants submit samples regularly for retesting to meet these criteria. It pays off. Every quality step helps shore up the company’s brand and protects the end user.
The risks with this compound reflect those of any high-purity chemical. Treat every container with respect. Respect for the compound translates into respect for your customers—who rely on the consistency and safety that only careful storage and handling can bring.
| Names | |
| Preferred IUPAC name | 4-(Butoxymethyl)-2-methoxyphenol |
| Other names |
Butyl Vanillyl Ether VBE p-Hydroxyphenethyl butyl ether Vanillin Butyl Ether |
| Pronunciation | /vəˈnɪl.il ˈbjuː.tɪl ˈiː.θər/ |
| Identifiers | |
| CAS Number | 82654-98-6 |
| Beilstein Reference | 969495 |
| ChEBI | CHEBI:34789 |
| ChEMBL | CHEMBL2103831 |
| ChemSpider | 126970 |
| DrugBank | DB11251 |
| ECHA InfoCard | ECHA InfoCard: 1000037-257 |
| EC Number | 83017-56-9 |
| Gmelin Reference | 1495025 |
| KEGG | C18762 |
| MeSH | C10H20O2, Vanillyl Butyl Ether, 82654-98-6, Butyl 4-hydroxy-3-methoxybenzyl ether, Pharmaceutical Preparations, Chemical Actions, Dermatologic Agents |
| PubChem CID | 100149 |
| RTECS number | WGK3 |
| UNII | 08J2K08A8I |
| UN number | UN1993 |
| CompTox Dashboard (EPA) | DTXSID8036014 |
| Properties | |
| Chemical formula | C13H20O3 |
| Molar mass | 252.33 g/mol |
| Appearance | Clear, pale yellow liquid |
| Odor | Faint vanilla odor |
| Density | 0.905 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.17 |
| Vapor pressure | <0.01 mmHg (25°C) |
| Acidity (pKa) | 13.7 |
| Basicity (pKb) | 5.6 |
| Magnetic susceptibility (χ) | -7.9×10⁻⁶ |
| Refractive index (nD) | 1.5210 |
| Viscosity | 10-20 mPa.s (at 20°C) |
| Dipole moment | 2.76 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 713.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -7128 kJ/mol |
| Hazards | |
| Main hazards | Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS labelling: GHS07, Signal word: Warning, Hazard statements: H315, H319, Precautionary statements: P264, P280, P305+P351+P338, P337+P313 |
| Pictograms | GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | Precautionary statements: P210, P233, P240, P241, P242, P243, P261, P264, P271, P272, P273, P280, P301+P310, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P312, P321, P330, P337+P313, P362+P364, P370+P378, P403+P235, P405, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | `113°C` |
| Autoignition temperature | 601°C |
| Lethal dose or concentration | LD50 (oral, rat) > 5000 mg/kg |
| LD50 (median dose) | > 1,300 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established. |
| REL (Recommended) | 3.3 mg/m³ |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Eugenol Vanillin Menthyl Lactate Menthoxypropanediol Ethyl Vanillin Butylated Hydroxyanisole (BHA) Menthyl Ether Vanillyl Alcohol |
Chengguan District, Lanzhou, Gansu, China
